Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: elx-02, mt-3724, citatuzumab bogatox +2 | 1.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 180 | 0.91 |
| pathways Reactome | 16 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 10667
Sealed predictions
- RPL10 in dopamine neurons, braak+0.47 (p 0.199) → +0.40 (p 0.288)receipt 10674
Swarm cases
receipt 10674: RPL10 in dopamine neurons, braak
- power
- full sample +0.40 (p 0.103, n 18), 95% CI -0.09 to +0.73. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.43 (p 0.072, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.48 (p 0.045, n 18). not the mix.
- skeptic
- leave-one-out range +0.32 to +0.47, sign flips 0; without severely affected donors +0.40 (p 0.103, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for RPL10 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts